Company: LENZ
Filing Date: 2025-11-10
Form Type: SCHEDULE 13D/A
Source: 0001193125-25-274461
Chunk: 0

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-10
Form: SCHEDULE 13D/A
Chunk 0
---
 as reported by the Issuer in the Form 10-Q.

| SCHEDULE 13D |

| CUSIP No. | 52635N103 |

| 1                                                                  |                                                    Versant Venture Capital VII, L.P. |
| 2                                                                  |                                                                                -a)(b |
| 3                                                                  |                                                                         SEC use only |
| 4                                                                  |                                                                                   WC |
| 5                                                                  |  Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) |
| 6                                                                  |                                                                             DELAWARE |
| Number of Shares Beneficially Owned by Each Reporting Person With: |                                                                     7   834,661.00   
                                                                     8         0.00   
                                                                     9   834,661.00   
                                                                       10        0.00 |
| 11                                                                 |                                                                           834,661.00 |
| 12                                                                 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) |
| 13                                                                 |                                                                                2.7 % |
| 14                                                                 |                                                                                   PN |

Comment for Type of Reporting Person: Consists of (i) 764,127 shares of Common Stock held by Versant VII (as defined in Item 2(a) of the Original Schedule 13D) and (ii) 70,534 shares of Common Stock issuable upon exercise of a warrant to purchase shares of Common Stock (the "Warrant") held by Versant VII. Versant Ventures VII GP-GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Versant Ventures VII GP (as defined in Item 2(a) of the Original Schedule 13D), which is the general partner of Versant VII. Each of Versant Ventures VII GP-GP and Versant Ventures VII GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VII. The percentage in Row 13 is based upon 31,360,503 shares of Common Stock, which consists of (i) 31,289,969 shares of Common Stock outstanding as of October 30, 2025, as set forth in the Form 10-Q, plus (ii) 70,534 shares of Common Stock issuable upon exercise of the Warrant held by Versant VII.

| SCHEDULE 13D |

| CUSIP No. | 52635N103 |

|